Introduction {#S0001}
============

Since the first birth of Louise Brown in the United Kingdom in 1978,[@CIT0001] in vitro fertilization (IVF) has flourished for more than 40 years and brought hope to many infertile couples as a major treatment alternative. Currently, more than seven million children have been conceived via IVF/intracytoplasmic sperm injection (ICSI), accounting for 1.6% of births in the United States and 1.0% in mainland China.[@CIT0002],[@CIT0003] However, compared with spontaneously achieved pregnancies, infants born after IVF/ICSI, whether singletons or multiples,[@CIT0004],[@CIT0005] have been widely reported at greater risks of adverse neonatal outcomes in terms of preterm birth (PTB), low birthweight (LBW), small-for-gestational age (SGA) and congenital malformations. Some studies suggest that the risks are attributable to the etiology of infertility,[@CIT0006] while others speculate the potential effects of the assisted reproduction technology itself, such as the controlled ovarian hyperstimulation (COH) protocol, embryo culture condition and cryopreservation technique.[@CIT0007]--[@CIT0009]

The process of COH is considered to be a key determinant in IVF/ICSI success by recruiting multiple dominant follicles and thereby increasing the quantity of oocytes retrieved within a single cycle. Routine COH regimens, using gonadotropin-releasing hormone (GnRH) agonists and antagonists, have been generally accepted as safe protocols based on the initial reassuring results of numerous prospective or retrospective follow-up studies on obstetrical complications and congenital malformations.[@CIT0010],[@CIT0011] Pituitary down-regulation with GnRH agonists promotes antral follicle synchronization, but poses a higher chance of ovarian hyperstimulation syndrome (OHSS) by human chorionic gonadotropin (hCG) trigger. While GnRH antagonists could suppress luteinizing hormone (LH) in a rapid and reversible manner without initial flare effects, a varied proportion (0.34--38%) of patients experienced premature LH surge, especially in women with advanced age and diminished ovarian reserve.[@CIT0012],[@CIT0013]

In 2015, we proposed a new COH protocol named progestin-primed ovarian stimulation (PPOS), in which exogeneous progesterone, adjuvant to human menopausal gonadotropin (hMG), was used from the early follicular phase to block the estradiol (E~2~)-induced positive feedback effects.[@CIT0014] Compared with the conventional GnRH-agonist short regimen, the PPOS protocol takes the advantage of an oral administration route to effectively prevent premature LH surge while achieving comparable oocyte retrieval and pregnancy outcomes.[@CIT0014] Coupled with dual trigger (GnRH agonist and a low dose of hCG) for final oocyte maturation and the application of a freeze-all strategy for viable embryos, it also allows for nearly complete avoidance of the OHSS incidence.[@CIT0015] In addition, the safety of PPOS protocol, using medroxyprogesterone acetate (MPA) or micronized progesterone (brand name: Utrogestan), has been demonstrated respectively in our large follow-up studies of 1931 and 855 newborns regarding neonatal outcomes and congenital malformations.[@CIT0016],[@CIT0017]

Dydrogesterone (DYG), which has a molecular structure as retroprogesterone, is a selective progesterone receptor agonist with high oral bioavailability.[@CIT0018] It is estimated that about 113 million women and 20 million fetuses have been exposed to DYG since 1960s in the treatment of a variety of conditions such as endometriosis, menstrual disorders and recurrent miscarriage.[@CIT0019] Moreover, we recently showed that DYG could also be applied as an alternative progestin in PPOS protocol with the strength of weaker pituitary suppression, thus leading to a lower dose and shorter duration of hMG stimulation during COH.[@CIT0020]

To date, the DYG + hMG protocol has resulted in over 1000 infants born after frozen-thawed embryo transfer (FET) cycles. However, the question remains whether this unique protocol is safe for the newborn population. Therefore, the aim of the present study was to comprehensively assess the neonatal outcomes and congenital malformations in children born after the DYG + hMG protocol in comparison with the conventional GnRH-agonist short protocol.

Materials and methods {#S0002}
=====================

Study design and participants {#S0002-S2001}
-----------------------------

This was a retrospective cohort study performed at the Department of Assisted Reproduction of Shanghai Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine. The study protocol was approved by the hospital's Ethics Committee (Institutional Review Board). Written informed consent was obtained from patients in accordance with the ethics committee protocol. All women who achieved clinical pregnancy after IVF/ICSI and subsequent FET cycles using the DYG + hMG protocol or the GnRH-agonist short protocol were enrolled from January 2014 to December 2017. Clinical pregnancy was defined as the presence of gestational sac with or without fetal heart activity, as measured by ultrasound examination 7 weeks after FET. Patients were excluded from the study if they reported pregnancy-related disorders such as gestational diabetes mellitus, hypertension, thyroid diseases and intrahepatic cholestasis of pregnancy, or adverse environmental exposure including cigarette smoking and alcohol consumption, in consideration of their possible associations with congenital malformations.[@CIT0021] We also excluded donor sperm cycles for their lower risks of LBW compared with partner sperm IVF/ICSI,[@CIT0022],[@CIT0023] as well as cycles with embryo cryopreservation for over 1 year to keep consistency between patient age at oocyte retrieval and at embryo transfer. Other exclusion criteria included core data missing such as fertilization method.

Treatment {#S0002-S2002}
---------

A detailed description of the ovarian stimulation protocols has been presented in our previous publications.[@CIT0020] Briefly, in the DYG + hMG protocol, patients were administered daily with 20 mg DYG (Duphaston, Abbott Biologicals, USA) and 150--225 IU hMG (Anhui Fengyuan Pharmaceutical Co., China) from menstrual cycle day 3 (MC3) to the day of trigger. In the GnRH-agonist short protocol, patients were injected daily with 0.1 mg triptorelin (Decapeptyl, Ferring Pharmaceuticals, Germany) from MC2 onward and 150--225 IU hMG from MC3 onward until trigger. The doses of hMG were adjusted according to ovarian response, as assessed by transvaginal ultrasound examination and serum E~2~ concentration. When at least three follicles reached 18 mm in diameter or one dominant follicle reached 20 mm, final oocyte maturation was co-triggered using 0.1 mg triptorelin and 1000 IU hCG (Lizhu Pharmaceutical Trading Co., China) for the DYG + hMG protocol, or triggered with 5000 IU hCG alone for the GnRH-agonist short protocol.

All follicles with a diameter over 10 mm were aspirated at 34--36 h after trigger. The retrieved oocytes were fertilized by conventional IVF and/or ICSI according to semen parameters. The zygotes were transferred and cultured in the Continuous Single Culture (Irvine Scientific, USA) throughout the entire developmental stage. According to the criteria described by Cummins et al.,[@CIT0024] only embryos classified as top-quality (grade I and II) were cryopreserved via vitrification on day 3 after oocyte retrieval, whereas suboptimal embryos (grade III and IV) were subjected to extended culture. The Gardner and Schoolcraft grade system was then applied to select morphologically good blastocysts (grade ≥3BC) for vitrification on day 5 or 6.[@CIT0025] The vitrification and thawing procedures were performed the same as those presented elsewhere.[@CIT0014]

As previously described,[@CIT0014],[@CIT0020] endometrial preparation for FET was performed in natural cycles, mild stimulation cycles or hormone replacement cycles, for women with regular menstruation, irregular menstruation or a history of thin endometrium, respectively. Up to two embryos per patient were transferred in each FET cycle. For luteal phase support, progesterone was administered with both oral DYG (40 mg/d; Fematon-yellow tablets, Abbott Biologicals, USA) and vaginal micronized progesterone (400 mg/d; Utrogestan, Besins Manufacturing, Belgium), and was continued to 10 weeks of gestations for those who achieved a pregnancy.

Follow-up of pregnancy and neonatal outcomes {#S0002-S2003}
--------------------------------------------

The newborn follow-up system at our department has been described previously.[@CIT0016],[@CIT0017],[@CIT0026] In brief, the couples completed telephone surveys by trained nurses during each trimester of pregnancy and up to 1 week after delivery. Standardized questionnaires were used to gather information including a wide range of pregnancy exposures, pregnancy complications, gestational weeks, mode of delivery, birth date and locality, birth weight and length, newborn gender as well as neonatal diseases. For the reporting of neonatal diseases, further interviews were conducted on the specific diagnosis, severity, treatment and final outcomes. For babies born in our university hospital, the medical records with detailed physical examination and routine ultrasound examination of the brain, kidney, and heart at the first week after birth were obtained, while written proof was acquired from the pediatrician in charge if the babies were born elsewhere. In cases of failed attempts to contact the couples, information was collected through the local family planning service agencies. Furthermore, for babies born with congenital malformations, a special nurse was designated for thorough review to guarantee their accordance with the case definition of the Chinese Birth Defects Monitoring Program.

Outcome measures and definitions {#S0002-S2004}
--------------------------------

The primary outcome of the study was the incidence of major congenital malformations. Other analyzed adverse neonatal outcomes included LBW, very LBW, PTB, very PTB, SGA, large-for-gestational age (LGA) and early neonatal death.

Major congenital malformations were defined and coded according to the Q codes (Q00--Q99) of the International Classification of Diseases, 10th Revision (ICD-10). LBW and very LBW were defined as birthweight below 2500 g and 1500 g, respectively. PTB and very PTB were defined as delivery before 37 and 32 completed weeks of gestation, respectively. For the standardization of birthweights, Z-scores were calculated after adjusting for the gestational age and the newborn gender, based on a set of general population reference values for Chinese singletons and twins.[@CIT0027],[@CIT0028] In addition, the SGA and LGA were defined as birthweight \<10th and \>90th percentiles, respectively. Early neonatal death was defined as the death of a live-born baby within 7 days of birth.

Statistical analysis {#S0002-S2005}
--------------------

For continuous variables, the normality was tested by the graphical use of histograms and Q-Q plots as well as the Shapiro-Wilk test. The data were presented as mean with standard deviation (SD) and differences between groups were compared with the Student's *t*-test or Mann-Whitney *U*-test, as appropriate. Categorical variables were described as frequency with rate, and Chi-square test or Fisher exact test was used for comparison.

The associations between the ovarian stimulation protocols (DYG + hMG versus GnRH-agonist short) and major congenital malformations as well as adverse neonatal outcomes were evaluated by binary logistic regression analysis. All potential cofounders were introduced for adjustment whether or not statistical differences between groups were observed, including maternal age (\<30, 30--34, 35--37, 38--40 or ≥41 years), maternal body mass index (BMI) (\<18.5, 18.5--24.9, 25.0--29.9 or ≥30 kg/m^2^), gravidity (0 or ≥1), parity (0 or ≥1), duration of infertility, infertility diagnosis (tubal factor, male factor, unexplained or combined/other), sperm origin (ejaculated, testicular or epididymal), fertilization method (IVF, ICSI, or IVF + ICSI), FET endometrial preparation (natural cycle, mild stimulation or hormone replacement therapy), endometrial thickness, number of embryos transferred (single or double) and embryo stage at transfer (cleavage or blastocyst). Furthermore, to account for the correlation between twin births reported by the same delivery, a generalized estimating equation model was applied to calculate crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs).

Statistical analysis was performed with the Statistical Package for the Social Sciences (version 20.0; SPSS Inc., USA). All *P*-values were based on two-sided tests and *P*\<0.05 was considered to be statistically significant.

Results {#S0003}
=======

The flow chart of the study design and participant selection was presented in [Figure 1](#F0001){ref-type="fig"}. In brief, 1399 clinical pregnancies led to 1429 live-born infants after treatment with the DYG + hMG protocol and 2127 live-born infants were resulted from 2095 clinical pregnancies after the GnRH-agonist short protocol. No significant differences were found between the two groups regarding the rates of ectopic pregnancy, pregnancy loss (including spontaneous and therapeutic abortion) in the first trimester, ongoing pregnancy, pregnancy loss in the second or third trimester, stillbirth, lost to follow-up and livebirth (all *P*\>0.05). There was a total of 17 elective terminations of pregnancy due to fetal malformations: 7 (0.50%) in the DYG + hMG protocol and 10 (0.48%) in the GnRH-a short protocol group (*P*=0.924).Figure 1Flow chart of the study.**Abbreviations:** DYG, dydrogesterone; hMG, human menopausal gonadotropin; GnRH, gonadotropin-releasing hormone.

The baseline characteristics grouped by ovarian stimulation protocols were shown in [Table 1](#T0001){ref-type="table"}. The two groups differed significantly in maternal age, endometrial preparation and number of embryos transferred (all *P*\<0.001). Specifically, the GnRH-agonist short protocol group had a higher age, more natural cycles and more double embryo transfers than the DYG + hMG protocol group. No significant differences were observed when maternal BMI, the proportion of nulliparity and nulligravida, infertility duration, infertility diagnosis, sperm origin, fertilization method, endometrial thickness and embryo stage at transfer were analyzed (all *P*\>0.05).Table 1Baseline characteristics grouped by ovarian stimulation protocolsDYG + hMG protocol (n=1151)Short protocol (n=1724)*P*-valueMaternal age (years)31.0±4.131.5±3.9\<0.001Maternal BMI (kg/m^2^)21.6±2.921.5±2.80.583Nulligravida, n (%)1051 (51.9)1565 (51.8)0.971Nulliparity, n (%)597 (91.3)893 (90.8)0.629Duration of infertility (years)3.7±2.43.7±2.60.098Infertility diagnosis, n (%)0.327 Tubal factor625 (54.3)970 (56.3) Male factor147 (12.8)237 (13.7) Unexplained121 (10.5)153 (8.9) Combined/other258 (22.4)364 (21.1)Sperm origin, n (%)0.052 Ejaculated1124 (97.7)1667 (96.7) Testicular21 (1.8)53 (3.1) Epididymal6 (0.5)4 (0.2)Fertilization method, n (%)0.201 IVF742 (64.5)1090 (63.2) ICSI283 (24.6)407 (23.6) IVF + ICSI126 (10.9)227 (13.2)FET endometrial preparation, n (%)\<0.001 Natural cycle421 (36.6)764 (44.3) Mild stimulation357 (31.0)521 (30.2) Hormone replacement therapy373 (32.4)439 (25.5)Endometrial thickness (mm)10.48±2.0710.62±2.100.627No. of embryos transferred, n (%)\<0.001 Single186 (16.2)193 (11.2) Double965 (83.8)1531 (88.8)Embryo stage at transfer, n (%)0.288 Cleavage stage997 (86.6)1469 (85.2) Blastocyst stage154 (13.4)255 (14.8)[^2][^3]

[Table 2](#T0002){ref-type="table"} demonstrated the neonatal outcomes in live-born singletons and twins. In total, 873 singletons and 556 twins were born after treatment with the DYG + hMG protocol, while 1321 singletons and 806 twins were born after the GnRH-agonist short protocol. In both singletons and twins, comparisons between the two groups did not reveal any significant difference in the mode of delivery, newborn gender, gestational age, birthweight, length at birth and Z-scores. With regard to adverse neonatal outcomes, the two groups were also similar in the proportion of LBW, very LBW, very PTB, SGA, LGA and early neonatal death among singletons and twins, and remained stable after adjusting for a variety of confounding factors ([Figure 2](#F0002){ref-type="fig"}). Notably, the incidence of PTB failed to reach significant difference between the two groups among singletons (8.8% vs 7.3%, *P*=0.266), but was slightly higher in the GnRH-agonist short protocol group among twins (52.9% vs 47.1%, *P*=0.038). This higher risk, however, was not maintained after adjustment (adjusted OR=0.85, 95% CI: 0.68--1.07).Table 2Neonatal outcome in live-born singletons and twins grouped by ovarian stimulation protocolsSingletonsTwinsDYG + hMG protocol (n=873)Short protocol (n=1321)*P*-valueDYG + hMG protocol (n=556)Short protocol (n=806)*P*-valueMode of delivery, n (%)0.1210.422 Vaginal231 (26.5)311 (23.5)18 (3.2)18 (3.2) Cesarean section642 (73.5)1010 (76.5)538 (96.8)788 (97.8)Gender, n (%)0.3440.232 Female435 (49.8)631 (47.8)248 (44.6)386 (47.9) Male438 (50.2)690 (52.2)308 (55.4)420 (52.1)Gestational age (weeks)38.5±1.438.4±1.70.14936.1±2.036.3±2.00.053 Preterm birth (\<37 weeks), n (%)64 (7.3)116 (8.8)0.226262 (47.1)426 (52.9)0.038 Very preterm birth (\<32 weeks), n (%)4 (0.5)15 (1.1)0.09428 (5.0)32 (4.0)0.346Birthweight (g)3367.5±471.33348.2±518.80.9302539.5±482.92549.5±467.50.785 Low birthweight (\<2500 g), n (%)31 (3.6)64 (4.8)0.145210 (37.8)302 (37.5)0.910 Very low birthweight (\<1500 g), n (%)2 (0.2)10 (0.8)0.17919 (3.4)19 (2.4)0.243Z-scores0.40±1.110.35±1.180.4990.29±0.960.35±0.950.117Small-for-gestational age (\<10th percentile), n (%)45 (5.2)80 (6.1)0.37319 (3.4)30 (3.7)0.767Large-for-gestational age (\>90th percentile), n (%)151 (17.3)249 (18.8)0.357130 (23.4)206 (25.6)0.360Length at birth (cm)50.1±1.749.9±1.70.10547.7±3.347.9±2.70.197Early neonatal death, n (%)0 (0.0)3 (0.2)0.4132 (0.4)2 (0.2)1.000[^4][^5] Figure 2Crude and adjusted odds ratios for adverse neonatal outcome in (**A**) singletons and (**B**) twins born after the DYG + hMG protocol compared with GnRH-agonist short protocol.**Abbreviations:** OR, odds ratio; DYG, dydrogesterone; hMG, human menopausal gonadotropin.

As presented in [Table 3](#T0003){ref-type="table"}, major congenital malformations were observed in 16 out of 1429 live-born infants (1.12%) in the DYG + hMG protocol and in 23 out of 2127 infants (1.08%) in the GnRH-agonist short protocol (*P*=0.914). No significant differences were found between the two groups when the incidence of major congenital malformations was analyzed according to the category of multiplicity and gender. In both groups, the main type of malformation occurred in the circulatory system (0.56% in the DYG + hMG protocol and 0.71% in the GnRH-agonist short protocol). After adjusting for confounders, no evidently elevated risk of major congenital malformations was observed in infants born after the DYG + hMG protocol in comparison with the GnRH-agonist short protocol in both singletons (adjusted OR=0.98, 95% CI: 0.40--2.39) and twins (adjusted OR=0.90, 95% CI: 0.33--2.41) ([Figure 2](#F0002){ref-type="fig"}).Table 3Major congenital malformations in live-born infants grouped by ovarian stimulation protocolsDYG + hMG protocol (All births n=1429)Short protocol (All births n=2127)*P*-valueInfants with malformations, n (%)16 (1.12)23 (1.08)0.914Category by multiplicity, n/N (%) Singletons9/873 (1.03)12/1321 (0.91)0.773 Twins7/556 (1.26)11/806 (1.36)0.867Category by gender, n/N (%) Female9/683 (1.32)10/1017 (0.98)0.520 Male7/746 (0.94)13/1110 (1.17)0.634Malformations in total, n1829-Malformation type, n- Q00--Q07 Nervous system00 Q10--Q18 Eye, ear, face, and neck02   Q16.1 Congenital absence of auditory canal01   Q17.0 Accessory auricle01 Q20--Q28 Circulatory system815   Q21.0 Ventricular septal defect15   Q21.1 Atrial septal defect25   Q21.2 Atrioventricular septal defect11   Q24.5 Malformation of coronary vessels10   Q24.9 Congenital malformation of heart, unspecified11   Q25.0 Patent ductus arteriosus22   Q28.2 Arteriovenous malformation of cerebral vessels01 Q30--Q34 Respiratory system10   Q33.0 Congenital cystic lung10 Q35--Q37 Cleft lip and cleft palate21   Q35.3 Cleft soft palate01   Q36.1 Cleft lip, median10   Q37 Cleft palate with cleft lip^a^10 Q38--Q45 Digestive system23   Q39.2 Congenital tracheo-esophageal fistula without atresia01   Q40.0 Congenital hypertrophic pyloric stenosis10   Q43.1 Congenital megacolon11   Q45.9 Congenital malformation of digestive system, unspecified01 Q50--Q56 Genital organs01   Q54.9 Hypospadias, unspecified01 Q60--Q64 Urinary system11   Q62.10 Congenital occlusion of ureter, unspecified01   Q63.1 Lobulated, fused and horseshoe kidney10 Q65--Q79 Musculoskeletal system12   Q66.4 Congenital talipes calcaneovalgus10   Q69.0 Accessory finger(s)01   Q69.1 Accessory thumb(s)01 Q80--Q89 Other malformations32   Q82.5 Congenital non-neoplastic nevus32 Q90--Q99 Chromosomal abnormalities02   Q90.9 Down syndrome, unspecified02[^6][^7]

Discussion {#S0004}
==========

In this large retrospective cohort study, we provided the first-time evidence that application of DYG in the PPOS protocol was a safe option for the newborn population without compromising neonatal outcomes or increasing congenital malformation risks.

Oocyte quality is strongly associated with early embryo survival, pregnancy establishment and maintenance, fetal growth and development, neonatal health, and even disease onset in adulthood.[@CIT0029] However, the relationship between oocyte quality and progesterone still remains to be controversial.[@CIT0030]--[@CIT0034] Silva et al found that when bovine cumulus-oocyte complexes were exposed to progesterone in vitro, the proportion of blastocyst formation was reduced by approximately 40%.[@CIT0030] This effect could be partially reversed by the progesterone receptor antagonist mifepristone.[@CIT0030] A study conducted by Zavareh et al showed that adding progesterone to the in vitro culture medium significantly inhibited oocyte meiotic resumption in a dose-dependent manner, thus leading to an increase in germinal vesicle arrest and reduction in oocyte maturation.[@CIT0031] In contrast, Carter et al demonstrated a neutral effect of elevated progesterone on the development of in vitro fertilized zygotes to the blastocyst stage.[@CIT0032] Yamashita et al, however, observed that the medium progesterone level was positively correlated with the rate of oocyte germinal vesicle breakdown (GVBD).[@CIT0034] The supplementation of ketoconazole, which suppressed the progesterone production of cumulus cells via demethylation of lanosterol, decreased the GVBD rate but could be overtaken by the addition of progesterone.[@CIT0034] Furthermore, the embryo development was also impaired by either inhibiting progesterone synthesis or blocking its receptor activity.[@CIT0033]

Despite the contradictory in vitro data on whether progesterone associates with oocyte quality in a positive or negative way, a consensus seems to be reached that high progesterone levels did not harm the oocyte/embryo developmental potentials in vivo. Several studies have reported that progesterone elevation on hCG trigger day adversely impacted on the rates of implantation and clinical pregnancy in fresh embryo transfer but not in FET or the donor/recipient cycles, suggesting the main detrimental effects of progesterone on endometrial receptivity rather than oocytes.[@CIT0035],[@CIT0036] In addition, a prospective cohort study of 322 pregnant women who used levonorgestrel, an exogenous progesterone for emergency contraception, demonstrated no association with the risks of pregnancy complications, major congenital malformations, or any other adverse neonatal outcomes.[@CIT0037] More directly, luteal-phase ovarian stimulation (LPS), where high levels of endogenous progesterone persisted during the entire process of follicle development with the use of letrozole and hMG, was proposed at our center in 2014.[@CIT0038] This novel regimen not only produced competent oocytes and high-quality embryos,[@CIT0038] but also showed its safety in the follow-up of 587 newborns compared with mild stimulation and GnRH-agonist short protocols.[@CIT0026] Encouraged by this discovery, we further applied exogenous progesterone, either MPA or micronized progesterone (brand name: Utrogestan), in combination with hMG for ovarian stimulation in IVF and achieved comparable outcomes in oocyte retrieval and pregnancy as well as neonatal health including congenital malformations.[@CIT0014],[@CIT0016],[@CIT0017],[@CIT0039]

DYG is a synthetic stereoisomer of progesterone with high oral bioavailability.[@CIT0018] Its unique molecular structural features provide high binding specificity and agonistic activity at progesterone receptors, but no or negligible activity at androgen, mineralocorticoid and glucocorticoid receptors, thus minimizing unwanted effects.[@CIT0018] Since the 1960s, the DYG has been applied to treat a variety of conditions related to progesterone deficiency.[@CIT0019] Recently, we also showed that DYG could effectively prevent premature LH surge during COH at a dose 5--10 times lower than micronized progesterone,[@CIT0040] and avoid profound pituitary suppression with a lower hMG dose than MPA.[@CIT0020] With regard to the offspring safety, a retrospective case-control study of 202 children reported a positive association between congenital heart diseases and DYG use in preventing miscarriage during early pregnancy.[@CIT0041] The study finding, however, is limited by its selection, confounding and information bias, and is challenged by the Lotus I and II Phase III studies showing that the incidence of serious adverse events as well as the congenital, familial and genetic disorders were similar in the newborn population between the oral DYG and micronized vaginal progesterone capsule or gel groups for luteal phase support.[@CIT0042],[@CIT0043] Nevertheless, all these studies were conducted in pregnant women when embryos had been implanted in the uterus. Due to the difference in structural and pharmacological characteristics between DYG and other exogenous progesterone,[@CIT0018],[@CIT0019] it remains unclarified whether DYG use for ovarian stimulation would exert any unsuspected influence on the oocyte quality and thereby neonatal health.

In the present study, we demonstrated that the DYG + hMG protocol was comparable to the classic GnRH-agonist short protocol in all neonatal outcomes and major congenital malformations in FET cycles after adjusting for various confounding factors. In line with previous studies,[@CIT0044] cardiovascular malformations were dominant among all types of defects in both protocols. No special type of malformations was observed, suggesting no specific teratogenic effect of DYG.

Notably, the total incidence of congenital malformations in live-birth infants in this study (1.10%) is lower than a data-linkage cohort study of IVF newborns in China (1.97%),[@CIT0044] while in accordance with report of the LPS, MPA + hMG and micronized progesterone (brand name: Utrogestan) + hMG protocols (1.02, 1.04 and 1.52%, respectively).[@CIT0016],[@CIT0017],[@CIT0026] The reasons could be elucidated in the following aspects. Firstly, in order to evaluate precisely the independent effect of ovarian stimulation protocols, we excluded participants with reported pregnancy-related disorders and adverse environmental exposures from data analysis, which were regarded to increase the risk of congenital malformations.[@CIT0021] Secondly, most of our data collections were carried out through paternal questionnaires without direct access to medical records. Therefore, some congenital malformations were likely to be omitted especially in children with minor or multiple defects, thus leading to an underestimation of the actual incidence. Finally, all infants in this study were born from FET cycles, where embryos were transferred into a more physiological endometrial environment than fresh embryo transfers. This could also lower the rate of congenital malformations, as indicated in previous studies.[@CIT0045]

The main strength of our study is the large sample size of over 3500 live-born infants at a single center, with 1429 newborns in the DYG + hMG protocol and 2127 in the GnRH-agonist short regimen. During the study period, no changes were made in our routine clinical practice including fertilization methods and vitrification or thawing procedures. The lost to follow-up rate was below 1% thanks to our highly specialized nurses, which further guaranteed the accuracy and reliability of neonatal data. However, the current study is limited by its retrospective and non-randomized design. Some baseline characteristics were inconsistent between the two groups. Although we adopted the binary regression analysis to reassure the robustness of results, possible unknown confounders may not be accounted for in the model.

Conclusion {#S0005}
==========

Our study suggested that DYG could serve as a feasible progestin in the PPOS protocol with satisfied neonatal outcomes and unelevated congenital malformation risk. Prospective randomized control trials with a larger sample size and continuous follow-up from birth to adulthood are needed to further validate the safety of this novel ovarian stimulation protocol.
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